Pharmaceutical composition for prevention or treatment of flavivirus infection
US12295967B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 24, 2019 |
| Grant date | May 13, 2025 |
| Priority date | — |
| Expiry date | Jul 6, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.